首页> 中文期刊> 《细胞与分子免疫学:英文版 》 >Downregulated cytotoxic CD8^(+)T-cell identifies with the NKG2A-soluble HLA-E axis as a predictive biomarker and potential therapeutic target in keloids

Downregulated cytotoxic CD8^(+)T-cell identifies with the NKG2A-soluble HLA-E axis as a predictive biomarker and potential therapeutic target in keloids

         

摘要

Keloids are an abnormal fibroproliferative wound-healing disease with a poorly understood pathogenesis,making it difficult to predict and prevent this disease in clinical settings.Identifying disease-specific signatures at the molecular and cellular levels in both the blood circulation and primary lesions is urgently needed to develop novel biomarkers for risk assessment and therapeutic targets for recurrence-free treatment.There is mounting evidence of immune cell dysregulation in keloid scarring.In this study,we aimed to profile keloid scar tissues and blood cells and found that downregulation of cytotoxic CD8^(+)T cells is a keloid signature in the peripheral blood and keloid lesions.Single-cell RNA sequencing revealed that the NKG2A/CD94 complex was specifically upregulated,which might contribute to the significant reduction in CTLs within the scar tissue boundary.In addition,the NKG2A/CD94 complex was associated with high serum levels of soluble human leukocyte antigen-E(sHLA-E).We subsequently measured sHLA-E in our hospital-based study cohort,consisting of 104 keloid patients,512 healthy donors,and 100 patients with an interfering disease.The sensitivity and specificity of sHLA-E were 83.69%(87/104)and 92.16%(564/612),respectively,and hypertrophic scars and other unrelated diseases exhibited minimal interference with the test results.Furthermore,intralesional therapy with triamcinolone combined with 5-fluorouracil drastically decreased the sHLA-E levels in keloid patients with better prognostic outcomes,while an incomplete reduction in the sHLA-E levels in patient serum was associated with higher recurrence.sHLA-E may effectively serve as a diagnostic marker for assessing the risk of keloid formation and a prognostic marker for the clinical outcomes of intralesional treatment.

著录项

  • 来源
    《细胞与分子免疫学:英文版 》 |2022年第4期|527-539|共13页
  • 作者单位

    Department of Plastic and Reconstructive Surgery;

    Ninth People’s Hospital;

    Shanghai Jiao Tong University School of Medicine;

    Shanghai;

    China;

    Department of Biostatistics;

    Epidemiology and Informatics;

    University of Pennsylvania Perelman School of Medicine;

    Philadelphia;

    PA;

    USA;

    Genekinder Medicaltech(Shanghai)Co.;

    Ltd;

    Shanghai;

    China;

    Department of Anatomy and Physiology;

    School of Medicine;

    Shanghai Jiao Tong University;

    Shanghai;

    China;

    Creative Biosciences(Guangzhou)Co.;

    Ltd.;

    Guangzhou;

    Guangdong;

    China;

    Department of Colorectal Surgery;

    Guangdong Institute of Gastroenterology;

    Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases;

    The Sixth Affiliated Hospital;

    Sun Yat-Sen University;

    Guangdong;

    China;

    Shanghai Institute of Immunology;

    Department of Immunology and Microbiology;

    Shanghai Jiao Tong University School of Medicine;

    Shanghai;

    China;

  • 原文格式 PDF
  • 正文语种 chi
  • 中图分类 整形外科学(修复外科学) ;
  • 关键词

    Keloid; Biomarker; T cell immunology;

相似文献

  • 中文文献
  • 外文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号